<DOC>
	<DOCNO>NCT02869945</DOCNO>
	<brief_summary>Parkinson 's disease onset clinically define appearance motor symptom include akinesia , tremor hypertonia . Several study show motor symptom occur least 50 % dopaminergic neuron lose . However , evidence suggest level dopaminergic denervation homogenous time diagnosis . Some patient high level dopaminergic loss disease onset indicate existence compensation mechanism . The aim study decipher metabolism dopamine involve compensation focus polymorphism COMT gene . This gene express accord two variant : ( ) COMT H encode form enzyme high level activity ( ii ) COMT L encode form enzyme low level activity . Thus , 3 possible genotype population : ( ) COMT HH associate increased degradation dopamine , ( ii ) COMT LL associate decreased degradation dopamine ( iii ) COMT HH ( intermediary COMT HH COMT LL ) . The hypothesis polymorphism COMT gene may participate compensation mechanism early PD . Patients COMT HH genotype may earlier motor symptom onset patient COMT LL genotype . To test hypothesis , recruit 51 patient de novo PD recruit ( 17 patient genotype ) . Given distribution COMT polymorphism population , maximum sample 76 patient screen recruit 17 patient genotype . Clinical evaluation include MDS-UPDRS , Non Motor Symptoms Scale , segmental symptom scale , Montreal Cognitive assessment , MMSE , Frontal assessment battery Parkinson 's disease behavioral assessment scale ( ECMP ) . All patient monophotonic emission tomography I-123-Ioflupane order ass level dopaminergic denervation MRI scan rest state study . Cerebrospinal fluid sample optional allow direct measurement dopamine metabolite . The main outcome measure level dopaminergic denervation I-123-Ioflupane scan accord COMT genotype , age , gender severity motor symptom MDS-UPDRS part 3 . If hypothesis confirm , allow test efficacy COMT inhibitor order delay dopaminergic drug initiation PD patient .</brief_summary>
	<brief_title>Compensation Mechanisms Parkinson 's Disease</brief_title>
	<detailed_description>Parkinson 's disease onset clinically define appearance motor symptom include akinesia , tremor hypertonia . Several study show motor symptom occur least 50 % dopaminergic neuron lose . However , evidence suggest level dopaminergic denervation homogenous time diagnosis . Some patient high level dopaminergic loss disease onset indicate existence compensation mechanism . The aim study decipher metabolism dopamine involve compensation focus polymorphism COMT gene . This gene express accord two variant : ( ) COMT H encode form enzyme high level aactivity ( ii ) COMT L encode form enzyme low level activity . Thus , 3 possible genotype population : ( ) COMT HH associate increased degradation dopamine , ( ii ) COMT LL associate decreased degradation dopamine ( iii ) COMT HH ( intermediary COMT HH COMT LL ) . The hypothesis polymorphism COMT gene may participate compensation mechanism early PD . Patients COMT HH genotype may earlier motor symptom onset patient COMT LL genotype . To test hypothesis , 51 patient de novo PD include ( 17 patient genotype ) . Given distribution COMT polymorphism population , maximum sample 76 patient screen inclusion 17 patient genotype . Only untreated patient include study order reliable assessment motor severity without interference dopaminergic drug . The study schedule follow : - At first visit ( V1 ) , inclusion criterion check patient sign inform consent . COMT genotype select patient analyze . - Result COMT genotype obtain within 4 week . Only 17 first patient genotype continue study - For patient , evaluation visit clinical assessment include MDS-UPDRS , Non Motor Symptoms Scale , segmental symptom scale , Montreal Cognitive assessment , MMSE , Frontal assessment battery Parkinson 's disease behavioral assessment scale ( ECMP ) performed.. All patient monophotonic emission tomography I-123-Ioflupane order ass level dopaminergic denervation . An MRI scan rest state study also perform assess compensation mechanism network level . Cerebrospinal fluid sample optional allow direct measurement dopamine metabolite . The main outcome measure level dopaminergic denervation I-123-Ioflupane scan accord COMT genotype without adjustment age , gender severity motor symptom MDS-UPDRS part 3 . Secondary outcome measure include : - level dopaminergic denervation compare across 3 genotype ( COMT HH , COMT HL COMT HH ) without adjustment age , gender motor score - determination functional compensation network scale assess fMRI rest state scan accord dopaminergic denervation - determination CSF dopamine metabolite profile time diagnosis ( CSF sample optional ) . If hypothesis confirm , allow test efficacy COMT inhibitor order delay dopaminergic drug initiation PD patient .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Man woman â‰¥ 18 year old , Caucasian origin Parkinson 's disease consider probable defined criterion UK Parkinson 's disease Brain Bank ( Hugues coll 2002 ) Absence antiparkinsonian medication Patient affilied social security system Signed information consent form Parkinsonian syndrome secondary neuroleptic Atypical parkinsonian syndrome multisystem atrophy , progressive supranuclear paralysis , dementia levy body . MRI contraindication ( claustrophobia , compatible mechanical heart valve MRI , pacemaker , cochlear implant , body ferromagnetic object , pregnancy ) MPET contraindication ( pregnancy , feeding , hypersensitivity ioflupane [ 123 ] Realization nuclear medicine examination year patient 's inclusion Patient guardianship trusteeship Any significant pathology could prevent patient participation achievement plan examination ( except lumbar puncture ) Patient participate participate biomedical research involve drug three month prior inclusion Specific exclusion criterion lumbar puncture accept patient : Anticoagulation antiplatelet treatment ; history hemostasis disorder ; platelet &lt; 150,000 mm3 ; TP &lt; 80 % ; TCA ( patient / control ) &gt; 1.2 . Hypersensitivity local anesthetic amide link excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>de novo untreated Parkinson Disease</keyword>
	<keyword>genetic</keyword>
	<keyword>COMT Polymorphism</keyword>
	<keyword>gene</keyword>
	<keyword>brain MRI</keyword>
	<keyword>brain MPET</keyword>
</DOC>